



Final Appraisal Recommendation

Advice No: 3612 – October 2012

Colecalciferol (Fultium-D₃[®]) 800 IU capsules

Submission by Internis Pharmaceuticals Ltd

Recommendation of AWMSG

Colecalciferol (Fultium-D₃[®]) is recommended as an option for use within NHS Wales for the prevention and treatment of vitamin D deficiency and as an adjunct to specific therapy for osteoporosis in patients with vitamin D deficiency or at risk of vitamin D insufficiency. Fultium-D₃[®] is indicated in adults, the elderly and adolescents.

Additional note:

- AWMSG is of the opinion that colecalciferol (Fultium-D₃[®]) may be appropriate for prescribing by all prescribers within NHS Wales for the above recommendation.

In reaching the above recommendation AWMSG has taken account of the AWMSG Secretariat Assessment Report (ASAR), the preliminary appraisal recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Marketing authorisation holder on first issue:	Internis Pharmaceuticals Ltd
Date of first issue	October 2012
Last reviewed	September 2016

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group. Final Appraisal Recommendation – 3612:
Colecalciferol (Fultium-D₃[®]) 800 IU capsules. October 2012.



NICE has accredited the process used by the All Wales Medicines Strategy Group (AWMSG) to produce its final appraisal recommendation. Accreditation is valid for 5 years from October 2011. More information on accreditation can be viewed at www.evidence.nhs.uk.

For full details on our accreditation visit: www.nice.org.uk/accreditation.